Arch Virol

1. TRAN TT, Andronicos NM, Ketheesan N, Walkden-Brown SW, et al
   Immune responses in chicken mucosal lymphoid tissues following oral and eye drop vaccination and revaccination with live modified vaccine of infectious laryngotracheitis virus (ILTV).
   Arch Virol. 2026;171:132.
   

   >> Share

   
   
2. AFZAL H, Umar M, Hoa NT, Ke GM, et al
   Enhancing the immunogenicity of a recombinant PEDV subunit vaccine: the role of lipoprotein signal peptide.
   Arch Virol. 2026;171:131.
   

   >> Share

   
   

   
   BMJ

3. TAYLOR L
   US vaccination: Judge blocks RFK Jr's controversial reforms.
   BMJ. 2026;392:s522.
   

   >> Share

   
   

   
   Clin Infect Dis

4. LOUBET P, Czernichow S, Giboin C, Sultan A, et al
   Recombinant vs Standard Influenza Vaccine in Adults With Severe Obesity: A Randomized Clinical Trial.
   Clin Infect Dis. 2026 Mar 19:ciag200. doi: 10.1093.
   

   >> Share

   
   
5. PALEFSKY JM, Giuliano AR, Goldstone SE, Dubin B, et al
   Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men.
   Clin Infect Dis. 2025 Oct 29:ciaf584. doi: 10.1093.
   

   >> Share

   
   

   
   J Infect

6. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia.
   J Infect. 2026;92:106727.
   

   >> Share

   
   

   
   J Infect Dis

7. ANGLEMYER A, Srinivas A, McNeill A, Allen CG, et al
   Large Reductions in Invasive Pneumococcal Disease and Related Morbidities Among Children in New Zealand After Change From PCV10 to PCV13.
   J Infect Dis. 2026;233:440-444.
   

   >> Share

   
   
8. FOLLMANN D, Dang L, Chu E, Fintzi J, et al
   A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.
   J Infect Dis. 2026;233:e646-e650.
   

   >> Share

   
   
9. SCHULTES OL, Hotwani A, Pavlinac PB, Hossain MJ, et al
   Defining Severe Shigellosis in the Enterics for Global Health Study: A Comparison of Leading Diarrhea Severity Definitions Among Children With Shigella Diarrhea.
   J Infect Dis. 2026;233:607-617.
   

   >> Share

   
   
10. 
    Correction to: Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
    J Infect Dis. 2026 Mar 18:jiag161. doi: 10.1093.
    

    >> Share

    
    
11. MIDDELDORP M, Duijster JW, Hoeve-Bakker BJA, Berkhof J, et al
    The long-term effect of two and three doses of bivalent HPV vaccination against HPV infections: a comparison between two observational cohort studies.
    J Infect Dis. 2026 Mar 18:jiag167. doi: 10.1093.
    

    >> Share

    
    
12. GRAY GC, Warren CJ, Webby RJ, Bowman AS, et al
    Why We Must Vaccinate US Dairy Cattle Against HPAI H5N1.
    J Infect Dis. 2026 Mar 20:jiag183. doi: 10.1093.
    

    >> Share

    
    

    
    Nat Immunol

13. KHURANA S, Posadas O, Kardava L, Coyle EM, et al
    Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.
    Nat Immunol. 2026 Mar 19. doi: 10.1038/s41590-026-02459.
    

    >> Share

    
    

    
    Nat Med

14. O'LEARY K
    One vaccine, no needles, broad protection.
    Nat Med. 2026 Mar 16. doi: 10.1038/d41591-026-00015.
    

    >> Share

    
    

    
    Pediatrics

15. EIDE HN, Haberg SE, Naess OE, Stephansson O, et al
    COVID-19 mRNA Vaccination in Pregnancy and Risk of Infection in Early Childhood.
    Pediatrics. 2026 Mar 20:e2025073661. doi: 10.1542/peds.2025-073661.
    

    >> Share

    
    

    
    PLoS Comput Biol

16. OKADA Y, Nishiura H
    Reconstructing the incidence rate and immune fraction of the population via a single snapshot survey: A case study of COVID-19 in Japan.
    PLoS Comput Biol. 2026;22:e1013990.
    

    >> Share

    
    

    
    PLoS Med

17. GRAY EJ, Cooper LV, Gonzalez AR, Mach O, et al
    Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study.
    PLoS Med. 2026;23:e1004952.
    

    >> Share

    
    
18. ABDEL-QADIR H, Bhatt HA, Swayze S, Paterson M, et al
    Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.
    PLoS Med. 2026;23:e1004924.
    

    >> Share

    
    

    
    PLoS One

19. MUKENGE EK, Lengo CN, Sumbu BM, Muwonga JM, et al
    Serum levels of immunoglobulin G and M antibodies against SARS-CoV-2 in asymptomatic individuals prior to COVID-19 vaccination in the Democratic Republic of Congo.
    PLoS One. 2026;21:e0343362.
    

    >> Share

    
    
20. WAMBUA J, Lang JC, Ogunjimi B, Hens N, et al
    Comparative analysis of the impact of chickenpox and herpes zoster vaccination in Belgium under two different exogenous boosting mechanisms.
    PLoS One. 2026;21:e0342896.
    

    >> Share

    
    
21. TAMIR TT, Agimas MC, Angaw DA
    Prevalence, spatial patterns and determinants of zero-dose vaccination among children aged 12-23 months in Sub-Saharan Africa: A multilevel spatial analysis.
    PLoS One. 2026;21:e0344293.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

22. FU C, Ma T, Clausen BE, Mellman I, et al
    Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity.
    Proc Natl Acad Sci U S A. 2026;123:e2518080123.
    

    >> Share

    
    

    
    Vaccine

23. HABIB MA, Domachowske JB, Senders S, Korbal P, et al
    Immunogenicity and safety of an investigational varicella zoster vaccine in toddlers aged 12-15 months: results of a phase II, controlled, randomized trial.
    Vaccine. 2026;79:128439.
    

    >> Share

    
    
24. LI K, Li Y, Zhang L, Fan C, et al
    Post-marketing surveillance of adverse events following enterovirus type 71 inactivated vaccine in China, 2016-2023.
    Vaccine. 2026;79:128443.
    

    >> Share

    
    
25. MCELHINNEY LM, Chaves LB, Petit C, Davis A, et al
    Workshop report: Improving standardisation of rabies serology methods and procedures.
    Vaccine. 2026;77:128369.
    

    >> Share

    
    
26. EKSTROM N, Liedes O, Vara S, Haveri A, et al
    Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals - A 3.5-year follow-up.
    Vaccine. 2026;77:128347.
    

    >> Share

    
    
27. IKRAR T, Muchsin W, Sophian A
    Maternal immunization against group B Streptococcus: Immune correlates, microbiome trade-offs, and global implementation challenges.
    Vaccine. 2026;77:128381.
    

    >> Share

    
    
28. BARBOZA APB, Luna-Muschi A, Faffe D, Borges IC, et al
    Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.
    Vaccine. 2026;77:128354.
    

    >> Share

    
    
29. HENG F, Magaret CA, Rouphael NG, Branche AR, et al
    The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.
    Vaccine. 2026;76:128348.
    

    >> Share

    
    
30. FRANCK Z, Hofstraat S, Jonker L, Kragten L, et al
    The evolving landscape of RSV immunization: Current policies and practices across Europe.
    Vaccine. 2026;76:128222.
    

    >> Share

    
    
31. PARIS L, Domegan L, O'Leary M, Hanrahan M, et al
    Protecting infants from respiratory syncytial virus (RSV) in Ireland: Impact of a national nirsevimab immunisation programme, 2024/2025.
    Vaccine. 2026;76:128344.
    

    >> Share

    
    
32. LI Z, Wang S, Zhang H, Li R, et al
    The Brucella abortus A19DeltafeuPDeltafeuQ double-mutant is highly attenuated and confers protection in BALB/c mice.
    Vaccine. 2026;76:128325.
    

    >> Share

    
    
33. QUACH HQ, Teodoro LI, Ratishvili T, Ovsyannikova IG, et al
    Seroprevalence of mumps and rubella antibodies among Indian children: evidence of a mumps immunity gap.
    Vaccine. 2026;76:128291.
    

    >> Share

    
    
34. HSU WL, Jiao Y, Hvasta M, Tran KN, et al
    A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge.
    Vaccine. 2026;76:128281.
    

    >> Share

    
    
35. DE LOOZE F, Essink BJ, van Boxmeer J, Andrade C, et al
    Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.
    Vaccine. 2026;79:128436.
    

    >> Share

    
    
36. DE OLIVEIRA PMN, Bosman R, Lucchesi MBB, Ogar C, et al
    Pharmacovigilance capacity and readiness of vaccine manufacturers in low- and middle-income countries: a maturity-based assessment of the pharmacovigilance system.
    Vaccine. 2026;79:128481.
    

    >> Share

    
    
37. BAMPI JVB, Arcanjo GGA, Santos KM, Ventura MS, et al
    Acceptability of a proposed new tuberculosis vaccine among people deprived of liberty in Brazil.
    Vaccine. 2026;79:128492.
    

    >> Share

    
    
38. KHAN A, Biswas P, Mondal S, Gundogdu O, et al
    Polymyxin B-treated outer membrane vesicles of Campylobacter jejuni as prospective mucosal vaccine candidates in chickens.
    Vaccine. 2026;79:128458.
    

    >> Share

    
    
39. ROOYAKKERS A, Ye L, Cahn PE, Ruiz-Palacios GM, et al
    Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
    Vaccine. 2026;79:128424.
    

    >> Share

    
    
40. AZEEZ R, Ames SR, Lotoski LC, Winsor GL, et al
    Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort.
    Vaccine. 2026;79:128342.
    

    >> Share

    
    
41. DEMIRDEN SF, Kimiz-Gebologlu I, Oncel SS
    Comparative evaluation of cell lines and their serum-free adapted derivatives for H1N1 influenza A virus propagation: bridging laboratory research and industrial vaccine production application.
    Vaccine. 2026;79:128489.
    

    >> Share

    
    
42. LUTZ CS, Cox SN, Courtney LP, Paulenich A, et al
    Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy: A targeted literature review.
    Vaccine. 2026;79:128408.
    

    >> Share

    
    
43. TWOHIG KA, Dalati H, David S, Bettinger JA, et al
    Association of perinatal care provider type with routine vaccination in first two years of life in British Columbia, Canada.
    Vaccine. 2026;79:128476.
    

    >> Share

    
    
44. TROCCOLI CS, Nascimento PS, Villar LM, Miguel JC, et al
    Long-term persistence of Seroprotection following a modified hepatitis B vaccine schedule in people living with HIV.
    Vaccine. 2026;79:128483.
    

    >> Share

    
    
45. VAN TRUONG L, Van Nguyen T, Trang VTT, Le TTT, et al
    Determinants of COVID-19 vaccine hesitancy across 186 countries: a multifaceted analysis using structural equation modeling.
    Vaccine. 2026;78:128196.
    

    >> Share

    
    
46. YE Q, Chen H, Jia B, Chen X, et al
    Uptake and effectiveness of a novel seasonal influenza vaccination campaign for school-age children in the 2023/2024 influenza season in Shanghai, China.
    Vaccine. 2026;79:128478.
    

    >> Share

    
    
47. HU S, Wang H, Yuan M, Zhao X, et al
    A nationwide survey on knowledge, attitude and practice regarding human papillomavirus (HPV), HPV-related disease and HPV vaccine among young adults in China.
    Vaccine. 2026;79:128473.
    

    >> Share

    
    
48. RIHS JB, Cirilo TM, Grossi de Oliveira AL, Amorim CCO, et al
    Evaluating Lactococcus lactis as a novel antiparasitic vaccine delivery platform: A scoping review of immunization routes and immunological outcomes.
    Vaccine. 2026;79:128431.
    

    >> Share

    
    
49. FERM DD, Nair A, Ferm JD, Liu H, et al
    Targeted mutagenesis in Ehrlichia canis deleting the phage head-to-tail connector protein gene and its assessment as a vaccine candidate preventing canine ehrlichiosis.
    Vaccine. 2026;79:128428.
    

    >> Share

    
    
50. AIZAWA Y, Shobugawa Y, Tachikawa J, Ikuse T, et al
    Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan.
    Vaccine. 2026;79:128474.
    

    >> Share

    
    
51. LLOYD PC, Shah PB, Zhang HT, Shah N, et al
    Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.
    Vaccine. 2026;79:128459.
    

    >> Share

    
    
52. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;79:128461.
    

    >> Share

    
    
53. GOODFELLOW L, Soble A, Malvolti S, Lambach P, et al
    The potential global health impact and net monetary benefit of programmatic use of improved influenza vaccines: a mathematical modelling study.
    Vaccine. 2026;60 Suppl 2:128455.
    

    >> Share

    
    
54. GIOVANATTI A, Shapiro AE
    Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability.
    Vaccine. 2026;79:128457.
    

    >> Share

    
    
55. WU Y, Su Y, Cao H, Wang Y, et al
    Chicken infectious Anemia virus impairs vaccination-induced antibody responses by suppressing CD40L expression.
    Vaccine. 2026;79:128429.
    

    >> Share

    
    
56. WU Y, Fu Y, Zuo C, Chen C, et al
    Gender differences in HPV vaccine hesitancy among college students: Implications for targeted health education strategies.
    Vaccine. 2026;79:128471.
    

    >> Share

    
    
57. CARRICO J, Parikh R, Shantakumar S
    Letter to the Editor: Impact of shingles vaccine tolerability on initiation and completion of the two-dose series in adults 50 years and older.
    Vaccine. 2026 Mar 12:128454. doi: 10.1016/j.vaccine.2026.128454.
    

    >> Share

    
    
58. MCEVOY R, Hervol JR, Zhang Y, Wagner EM, et al
    A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2026;79:128460.
    

    >> Share

    
    
59. LLANES-KIDDER C, Gaythorpe K, Rawson T
    Sociodemographic factors influencing COVID-19 vaccine uptake and dropout rates in England.
    Vaccine. 2026;79:128477.
    

    >> Share

    
    
60. COSTANTINO V, Notaras A, MacIntyre CR
    Long COVID in children in Australia and the potential impact of vaccination.
    Vaccine. 2026;79:128442.
    

    >> Share

    
    
61. MRZEL M, Danis K, Ucakar V
    Low uptake rotavirus vaccine: A study of vaccine effectiveness against rotavirus-related hospitalization based on electronic health records, Slovenia, 2019-2023.
    Vaccine. 2026;79:128440.
    

    >> Share

    
    
62. IRVING SA, Crane B, Daley MF, Dixon BE, et al
    2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.
    Vaccine. 2026;79:128441.
    

    >> Share

    
    

    
    Virology

63. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share